Julia Grigorieva

Mass Spectrometry to Classify Non–Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study

Fumiko Taguchi, Benjamin Solomon, Vanesa Gregorc et al. · JNCI Journal of the National Cancer Institute · 2007 · 315 citations · Full text

Medicine, Oncology, Pharmacology +16

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial

Vanesa Gregorc, Silvia Novello, Chiara Lazzari et al. · The Lancet Oncology · 2014 · 158 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial

David P. Carbone, Keyue Ding, Heinrich Röder et al. · Journal of Thoracic Oncology · 2012 · 108 citations · Full text

Medicine, Oncology, Pharmacology +14

A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma

Jeffrey S. Weber, Mario Sznol, Ryan J. Sullivan et al. · Cancer Immunology Research · 2017 · 72 citations · Full text

Life Sciences, Cancer Biology, Oncology +17

Differentiating Proteomic Biomarkers in Breast Cancer by Laser Capture Microdissection and MALDI MS

Melinda E. Sanders, Eduardo Dias, Baogang Xu et al. · Journal of Proteome Research · 2008 · 64 citations

Medicine, Cancer Biology, Oncology +17